Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.

Luca MastorinoPaolo DapavoCaterina CaritiSara SuscaNiccolò SiliquiniMichela OrtoncelliElena StroppianaAnna VerroneIsotta Giunipero di CorteranzoFrancesco LeoPietro QuaglinoSimone Ribero

Published in: Journal of personalized medicine (2024)

Secukinumab showed effectiveness for up to 5 years of treatment, with a high DS and achievement of PASI100, PASI90, and PASI < 3 at these time points. Only obesity reduced the response and maintenance of DS.

Keyphrases

ankylosing spondylitis
randomized controlled trial
systematic review
metabolic syndrome
insulin resistance
type diabetes
weight loss
weight gain
emergency department
high fat diet induced
rheumatoid arthritis
free survival
adipose tissue
adverse drug